Skip to main content

You are here

SARC Clinical Trials

Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world at ClinicalTrials.gov.

Patient participating in sarcoma trial

Active SARC Trials

SU2C - SARC032 - SPORE05

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab

Type of Sarcoma: Soft Tissue Sarcoma of the Extremity

Drug: Pembrolizumab

Accrual Status: Recruiting

Overall Study Principal Investigator:

David Kirsch, MD, PhD
Professor, Radiation Oncology / Professor of Pharmacology and Cell Biology
Duke University

GO TO CLINICALTRIALS.GOV

SARC033 - SPORE06

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Type of Sarcoma: Epithelioid Hemangioendothelioma

Drug: Trametnib

Accrual Status: Recruiting

Overall Study Principal Investigator:

Scott Schuetze, MD, PhD
Division of Hematology/Oncology
University of Michigan

GO TO CLINICALTRIALS.GOV

SARC031

MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors

Type of Sarcoma: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)

Drug: Selumetinib in combination with Vistusertib

Accrual Status: Not Yet Recruiting

Overall Study Principal Investigator:

AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

GO TO CLINICALTRIALS.GOV

SARC028

A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

Type of Sarcoma: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma

Drug: Pembrolizumab

Accrual Status: Recruiting

Overall Study Principal Investigator:

Hussein Tawbi, MD
Associate Professor of Medicine
MD Anderson Cancer Center

GO TO CLINICALTRIALS.GOV

SARC024

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas

Type of Sarcoma: Refractory liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcomas

Drug: Regorafenib and placebo (for liposarcoma and osteogenic sarcoma only)

Accrual Status: Recruiting

Overall Study Principal Investigator:

Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

Richard F. Riedel, MD
Associate Professor of Medicine
Duke University School of Medicine

Christopher W. Ryan, MD
Medical Oncologist
Oregon Health and Science University

Steven Attia, DO
Medical Oncologist
Mayo Clinic

GO TO CLINICALTRIALS.GOV

SARC023

SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Type of Sarcoma: Phase I all unresectable soft tissue or bone sarcomas and Phase II unresectable malignant peripheral nerve sheath tumor (MPNST)

Drug: Ganetespib and Sirolimus

Accrual Status: Not Recruiting

Overall Study Principal Investigator:

AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

GO TO CLINICALTRIALS.GOV

SARC016

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Type of Sarcoma: Malignant Peripheral Nerve Sheath Tumor (MPNST) either Sporadic or NF1 Associated

Drug: Bevacizumab and Everolimus

Accrual Status: Not Recruiting

Overall Study Principal Investigator:

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

GO TO CLINICALTRIALS.GOV

SARC012

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Type of Sarcoma: Osteosarcoma

Drug: Saracatinib and Placebo

Accrual Status: Not Recruiting

Overall Study Principal Investigator:

Melinda Merchant, MD, PhD
Staff Clinician, Pediatric Oncology Branch
National Cancer Institute

GO TO CLINICALTRIALS.GOV

SARC009

Trial of Dasatinib in Advanced Sarcomas

Type of Sarcoma: Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)

Drug: Dasatinib

Accrual Status: Not Recruiting

Overall Study Principal Investigator:

Scott Schuetze, MD, PhD
University of Michigan

GO TO CLINICALTRIALS.GOV

ESP1 / SARC025 - SPORE03

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

Type of Sarcoma: Ewing Sarcoma

Drug: Niraparib and Temozolomide or Irinotecan

Accrual Status: Recruiting

Overall Study Principal Investigator:

Sandra Strauss, MD, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute

Rashmi Chugh, MD
Assistant Professor
University of Michigan

GO TO CLINICALTRIALS.GOV

Closed SARC Trials

SARC022

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

Type of Sarcoma: Gastrointestinal stromal tumors

Drug: OSI-906

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC021

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Type of Sarcoma: Locally advanced or metastatic soft tissue sarcoma

Drug: TH-302 combined with doxorubicin vs. doxorubicin alone

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC020

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Type of Sarcoma: Advanced or Metastatic Untreated Soft Tissue Sarcoma

Drug: Trabectedin Infused to Doxorubicin

Accrual Status: Terminated

GO TO CLINICALTRIALS.GOV

SARC019

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Type of Sarcoma: Metastatic GIST

Drug: Imatinib

Accrual Status: Terminated

GO TO CLINICALTRIALS.GOV

SARC018 - SPORE01

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Type of Sarcoma: Metastatic Leiomyosarcoma

Drug: Mocetinostat & Gemcitabine

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC011

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Type of Sarcoma: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma

Drug: R1507

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC007

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

Type of Sarcoma: Chondrosarcoma, extra-skeletal myxoid chondrosarcoma or alveolar soft part sarcoma

Drug: Perifosine

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC006

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Type of Sarcoma: Malignant peripheral nerve sheath tumors sporadic or NF1 associated

Drug: Adriamycin/ifosfamide and Adriamycin/etoposide

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC005

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Type of Sarcoma: Uterine Leiomyosarcoma

Drug: Gemcitabine and Docetaxel

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC004

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

Type of Sarcoma: Dermatofirbrosarcoma Protuberans

Drug: Gleevec (Imatinib Mesylate)

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC003

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Type of Sarcoma: Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma

Drug: Gemcitabine and Docetaxel

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC002

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

Type of Sarcoma: Unresectable soft tissue sarcoma

Drug: Gemcitabine and Docetaxel

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC001

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Type of Sarcoma: Ewing's Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)

Drug: Imatinib Mesylate (Gleevec)

Accrual Status: Completed

GO TO CLINICALTRIALS.GOV